AyuVis Research
Pre-clinicalCOVID-19- and SARS-induced ARDS AyuVis research is developing a new class of drugs to treat complicated respiratory infections such as BPD and PAP with promising preclinical data. Both of these indications are associated with ARDS, which can be induced by the Corona virus.
Founded
2016
Focus
Small Molecules
About
COVID-19- and SARS-induced ARDS AyuVis research is developing a new class of drugs to treat complicated respiratory infections such as BPD and PAP with promising preclinical data. Both of these indications are associated with ARDS, which can be induced by the Corona virus.
Funding History
10Total raised: $20.0M
Grant$280KNHLBIApr 29, 2024
Grant$895KNICHDApr 12, 2024
Grant$204KNICHDMay 25, 2023
Grant$271KNHLBIApr 30, 2023
Company Info
TypePrivate
Founded2016
LocationLouisville, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile